Study is showing promise in reducing cardiovascular events by 20% with high risk patients..BD
Interim results from the ACCOMPLISH (Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension) trial demonstrate that high-risk, high blood pressure patients treated with Lotrel(R) (amlodipine besylate and benazepril HCl) had 20% fewer cardiovascular events than those taking a benazepril and hydrochlorothiazide (HCTZ) combination. This is the first cardiovascular outcomes trial in a hypertensive population where all patients were randomized to receive a single-pill combination treatment at the onset of the trial as opposed to a step care regimen. Lotrel is approved for the treatment of high blood pressure. It should not be used before other medications have been tried first.
Study is showing promise in reducing cardiovascular events by 20% with high risk patients..BD
Lotrel, A Single Pill Combination For Treating High Blood Pressure, Reduced Cardiovascular Events By 20% In High-Risk Patients